Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

WuXi Beats Financial Estimates in Q1

publication date: May 10, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
WuXi PharmaTech, one of China’s most visible CRO/CMOs, reported first quarter revenues that were slightly better than expected, up 16% at $93.6 million. The company’s lab service revenues increased 12%, but the star performer was contract manufacturing, which climbed 35% to $19.1 million. GAAP net income was up 17% at $18.2 million, or 24 cents per share. More details....

Stock Symbol: (NYSE: WX)     Share this with colleagues:  

 


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners